Alkeon Capital Management LLC Blueprint Medicines Corp Transaction History

Alkeon Capital Management LLC

$47.1 Billion
Q1 2025

A detailed history of Alkeon Capital Management LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Alkeon Capital Management LLC holds 900,628 shares of BPMC stock, worth $91.4 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

900,628

Previous 800,628 12.49%

Holding current value

$91.4 Million

Previous $69.8 Million 14.15%

% of portfolio

0.17%

Previous 0.14%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$86.69 - $115.63 $8.67 Million - $11.6 Million	100,000 Added 12.49%	900,628 $79.7 Million
Q4 2024 Feb 13, 2025	BUY	$82.48 - $101.39 $6.74 Million - $8.28 Million	81,700 Added 11.36%	800,628 $69.8 Million
Q3 2024 Nov 13, 2024	SELL	$84.1 - $120.5 $14.7 Million - $21.1 Million	-175,000 Reduced 19.58%	718,928 $66.5 Million
Q2 2024 Aug 13, 2024	BUY	$85.18 - $108.78 $8.52 Million - $10.9 Million	100,000 Added 12.6%	893,928 $96.3 Million
Q1 2024 May 14, 2024	BUY	$73.17 - $99.79 $11 Million - $15 Million	150,000 Added 23.29%	793,928 $75.3 Million
Q4 2023 Feb 13, 2024	SELL	$43.96 - $92.84 $13.2 Million - $27.9 Million	-300,000 Reduced 31.78%	643,928 $59.4 Million
Q2 2023 Aug 11, 2023	BUY	$42.2 - $66.37 $25 Million - $39.3 Million	591,745 Added 168.02%	943,928 $59.7 Million
Q1 2023 May 12, 2023	SELL	$37.97 - $50.0 $2.81 Million - $3.7 Million	-74,085 Reduced 17.38%	352,183 $15.8 Million
Q4 2022 Feb 13, 2023	SELL	$41.06 - $66.48 $28.5 Million - $46.1 Million	-693,144 Reduced 61.92%	426,268 $18.7 Million
Q3 2022 Nov 10, 2022	BUY	$49.93 - $77.7 $2.22 Million - $3.46 Million	44,512 Added 4.14%	1,119,412 $73.8 Million
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $3.12 Million - $4.84 Million	-68,999 Reduced 6.03%	1,074,900 $54.3 Million
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $6.96 Million - $14.2 Million	-128,601 Reduced 10.11%	1,143,899 $73.1 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $16.2 Million - $21.9 Million	200,000 Added 18.65%	1,272,500 $131 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $8.28 Million - $10.1 Million	100,000 Added 10.28%	1,072,500 $94.3 Million
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $6.8 Million - $8.12 Million	75,000 Added 8.36%	972,500 $94.6 Million
Q3 2020 Nov 16, 2020	BUY	$66.45 - $92.7 $12.3 Million - $17.1 Million	185,000 Added 25.96%	897,500 $83.2 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $22.8 Million - $31.7 Million	-400,000 Reduced 35.96%	712,500 $55.6 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $37.3 Million - $63.7 Million	775,000 Added 229.63%	1,112,500 $65.1 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $10 Million - $12.4 Million	150,000 Added 80.0%	337,500 $27 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $4.56 Million - $6.34 Million	62,500 Added 50.0%	187,500 $13.8 Million
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $4.84 Million - $8.6 Million	-99,346 Reduced 44.28%	125,000 $10 Million
Q4 2018 Feb 14, 2019	BUY	$45.57 - $74.26 $10.2 Million - $16.7 Million	224,346 New	224,346 $12.1 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $14.4 Million - $19.2 Million	-245,075 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $8.14 Million - $13.5 Million	133,500 Added 119.65%	245,075 $15.6 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $7.44 Million - $10.5 Million	101,575 Added 1015.75%	111,575 $10.2 Million
Q4 2017 Feb 15, 2018	BUY	$62.91 - $88.32 $629,100 - $883,199	10,000	10,000 $754,000

Others Institutions Holding BPMC

# of Institutions

390

Shares Held

68.6M

Call Options Held

1.54M

Put Options Held

1.08M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.06B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alkeon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alkeon Capital Management LLC with notifications on news.

Account

Alkeon Capital Management LLC Blueprint Medicines Corp Transaction History